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Like the other WHO-listed Neglected Tropical Diseases (NTDs), snakebite primarily affects rural, impoverished
tropical communities that lack adequate health resources. The annual 138 000 deaths and 400 000 disabil-
ities suffered by these subsistence farming communities means that snakebite is an additional cause and
consequence of tropical poverty. Unlike most of the NTDs, however, snakebite is a medical emergency, and
requires rapid treatment in a hospital equipped with effective antivenom, beds and appropriately trained staff.
The lack of such facilities in the remote areas most affected by snakebite, and the high treatment costs,
explains why most victims, particularly in sub-Saharan Africa, consult traditional healers rather than seek hos-
pital care. Whilst affordable, there is no evidence that traditional treatments are effective. The number of
snakebite victims that die, unregistered, in the community is threefold higher than hospital-recorded deaths.
After decades of inertia, WHO beneﬁtted from advocacy interventions and the support of key agencies,
including Médecins Sans Frontières, the Wellcome Trust, the Koﬁ Annan Foundation and the Global Snakebite
Initiative, to recently institute transformative actions for reducing the public health burden of tropical snake-
bite. It is imperative that WHO and the other stakeholders now gain the support and investment of govern-
ments, research funders and donor agencies to ensure that this recent momentum for change is translated
into sustained beneﬁt to snakebite victims.
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Introduction
Tropical snakebite was a major focus of the 2018 annual meet-
ing of the Royal Society of Tropical Medicine & Hygiene, and the
society also launched International Snakebite Awareness Day.
These events exemplify the rapid, very recent change in percep-
tion of the public health importance of tropical snakebite. Two
decades ago, it was society members Theakston and Warrell’s
paper entitled ‘Crisis in snake antivenom supply for Africa’1 that
ﬁrst reported that tropical snakebite victims are forced to live in
a therapeutic vacuum leading to increased rates of mortality
and morbidity.
Despite the important message of this and several other
academic papers,2–6 little changed in the following 15 years to
reduce the estimated 138 000 snakebite victims who die each
year from respiratory paralysis, hypovolemic shock or uncon-
trolled bleeding.6 To put this into perspective: snakebite glo-
bally kills one quarter of the number of people dying from
malaria every year; in India, half the number of people dying
from HIV are killed by snakebite (46 000 per annum); and more
people are killed each month by venomous snakes than the
11 300 people that died during the 2014–2016 West African
Ebola crisis. The 400 000 surviving snakebite victims left annu-
ally with life-changing physical disabilities7 or psychological
trauma8 add substantially to the disease burden posed by
tropical snakebite.
The following sections summarise the circumstances that
identify tropical snakebite as a consequence and cause of rural
tropical poverty, and why it can be described as perhaps the
most marginalised, high-mortality, high morbidity, Neglected
Tropical Disease (NTD).
Snakebite victims typically live in
impoverished, remote subsistence farming
communities
Poor farmers are dependent upon non-mechanised agricultural
techniques that place them at increased risk from snakebite.
Peaks in snakebite are often coincident with rain seasons because
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the fall in temperature and ground-ﬂooding drives venomous
snakes into closer contact with farmers just as their agricultural
activities increase.9 Young adult farmers are therefore the highest
risk group for snakebite,10 and the loss of their income and food
production can drive families into extreme poverty. Inexpensively
constructed homes of mud walls and thatched roofs provide little
protection against the entry of snakes preying upon rodents
attracted to the food, water or chickens within. Inhabitants sleep-
ing on the ﬂoor or without bed nets are additionally vulnerable to
snakebite at night. Limited electricity supplies also mean that
snakes are less visible at dusk/night—a time when they are par-
ticularly active. Children are the second highest risk group and
are bitten while undertaking chores (e.g. herding) or playing (e.g.
catching rats) and other activities less common in more afﬂuent
communities. The long-term disability and disﬁgurement suffered
by surviving children frequently results in permanent loss of edu-
cation and income, and the detrimental effects of stigmatisation.
The suspected effects of chronic psychological sequalae upon
income and quality of life has yet to be adequately determined.
Delayed access of victims to effective
healthcare
Snakebite is a medical emergency requiring rapid treatment. But
the communities at greatest risk are typically located far from
effective healthcare and lack access to adequate/reliable ambu-
latory services. The closest clinic/health centres rarely possess the
resources to effectively treat snakebite. Victims therefore often
need to travel long, costly distances for several distressing hours
before locating a hospital with the requisite clinical capacity. This
delay increases the severity of envenoming and likelihood of
death. Threefold the number of snakebite deaths recorded from
hospital data occur in the community—and these lives lost are
therefore not generally recorded.11 Cultural circumstances can
add to these logistic barriers to accessing effective healthcare.
Thus, reports from communities identify that many rural snake-
bite victims do not seek hospital treatment because the bite is
often perceived as a manifestation of witchcraft or deity displeas-
ure,12 and that hospital treatment will not reverse these.
Effective treatment is often unavailable and
unaffordable to communities in greatest
need, especially in Africa
Antivenom is the drug of choice for treating snakebite and is
immunoglobulin puriﬁed from the blood of horses/sheep hyperim-
munised with snake venom(s). The efﬁcacy of an antivenom is
largely restricted to the snake species/genus whose venom(s) were
used for immunisation. For example, an antivenom designed to
treat cobra envenoming will not be effective against a puff adder
envenoming, which limits both the clinical utility and economy-of-
scale manufacturing incentives of current antivenoms. The tragedy
of sub-Saharan Africa is that the vast majority of available antive-
noms (>90% by one estimate) are poorly effective,13,14 and some
are dangerously ineffective15,16 because they are either manufac-
tured with venoms from non-African snakes, or they possess low
concentrations of effective immunoglobulins. The Africa-wide
distribution success of these inadequate products is primarily
because (i) their retail costs (US$30–90/vial13,14) are a fraction of
that of effective products (US$315/vial for the South Africa
vaccine producers SAIMR’s products), and (ii) manufacturers of
the most effective African antivenoms (Behringwerke and
Sanoﬁ Pasteur) ceased production because of low government
demands and commercial inability to out-compete the cheaper
but routinely less effective brands.17
Effective snakebite treatment typically requires 2–10 vials of
antivenom and these costs are very rarely subsidised in Africa. The
typical annual income for an African subsistence farmer is US$-
600–700. Antivenom treatment, if available and effective, is there-
fore rarely affordable for most African victims. High treatment and
transport costs, and poor effectiveness of treatment often leads to
a loss of conﬁdence in standard health systems and means that
rural snakebite victims often ﬁrst consult a local, trusted and
affordable traditional healer. Unfortunately, while affordable, there
is no evidence that traditional treatments are effective.
All of this means that snakebite victims in sub-Saharan
Africa have been failed for decades by the absence of adequate
responses from governments and international health agencies.
Raising global awareness and effecting
change
It required the intervention of global champions of disadvan-
taged populations to raise awareness and effect change. This
started in 2015 with the widely publicised Médecins Sans
Frontières report of the marginalisation of tropical snakebite
from the agendas of relevant government and international
health agencies.18 The Wellcome Trust sponsored a multi-
stakeholder ‘Mechanisms to reverse the public health neglect of
snakebite victims’ meeting in September 2015 that outlined the
challenges and opportunities to address this topic.19 In
December 2016, Mr and Mrs Koﬁ Annan convened the important
‘Snakebites in Africa: Challenges and Solutions’ conference that
brought together representatives from WHO and from key fund-
ing agencies and NGOs along with snakebite clinicians and
scientists to identify priority actions.20 Following that confer-
ence, and with the support of the Koﬁ Annan Foundation,
Médecins Sans Frontières, the Global Snakebite Initiative, Health
Action International, and several governments and academics,
WHO listed tropical snakebite as a priority NTD in 2017—a deci-
sion ratiﬁed by the World Health Assembly in April this year.21
During the process of this recent transformative change for
tropical snakebite, WHO also instituted an antivenom risk-
assessment programme designed to identify effective and inef-
fective brands of antivenoms marketed in Africa. Results of that
assessment, including WHO procurement recommendations,
are being released in the near future. WHO has also convened a
Snakebite Envenoming Working Group (a widely consultative
body) of experts to design a strategy to halve the global mortal-
ity and morbidity caused by tropical snakebite by 2030. The
complexities of this important task and its need for substantive
support and investment were made clear by the late Mr Koﬁ
Annan in his ‘Snakebite: The biggest public health crisis you’ve
never heard of’ address last June, in which he stated: ‘I strongly
believe that snakebite envenoming poses a serious public health
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challenge. But it is a challenge that can be surmounted. This is a
forgotten crisis, and we need to take immediate, robust, and
sustained action to confront it. By working together to tackle
snakebite, we can save the lives of tens of thousands of our fel-
low human beings in some of the poorest and most margina-
lised parts of our world.’22
Mr Annan understood the signiﬁcant barriers faced by tropical
snakebite victims, and his global stature and persuasive voice has
helped galvanise WHO engagement with key health decision-
makers in governmental, international and philanthropic donor
agencies. There is an urgent need to utilise this new momentum
to garner substantive global investment in a number of actions
at every stage in the snakebite victims’ route to recovery:
• Delivery of community education campaigns to reduce the inci-
dence of snakebite and to promote the accessing of hospital care.
• Investment in capacity strengthening of local ambulance and
health infrastructures so that victims have rapid access to
health facilities equipped with effective antivenoms, and
investment in training of clinical staff.
• Establishment of regional antivenom-efﬁcacy testing centres
to ensure that inappropriate antivenoms are excluded from
distribution.
• Urgent investment in clinical trials of existing and new antive-
noms, particularly in Africa.
• Engagement of governments and other stakeholders with
manufacturers and distributors of effective antivenoms to
ensure a substantial increase in production and a regular sup-
ply of their outputs at affordable prices.
• Establishment of in-country surveys to accurately identify
where snakebite incidence, mortality and morbidity is great-
est, and thereby improve antivenom delivery to priority areas.
• Scientiﬁc support for the development of new products and
diagnostic tools that are affordable, effective against all
regional snakes and safe enough to be used in the community.
These actions will require support from many different individuals
and agencies. However, global and sustained change requires a
coordinated response, and WHO with its many supporters is per-
haps the only agency with the requisite reach and inﬂuence. Donor
agencies need to provide WHO with the investment it needs to
implement its strategic plan. Effective delivery of this combination
of outputs will substantially and sustainably reduce tropical snake-
bite as a global health concern and demonstrate that the health
needs of the world’s snakebite victims are no longer neglected.
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